| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 48.902 | 39.978 | 29.181 | 41.882 | 29.439 | 9.510 | 2.507 | 426 | 1.830 | 1.598 |
| Total Income - EUR | 49.011 | 39.979 | 29.181 | 41.890 | 29.445 | 9.510 | 2.507 | 430 | 1.830 | 1.598 |
| Total Expenses - EUR | 61.393 | 12.619 | 22.533 | 34.701 | 22.737 | 10.556 | 6.229 | 285 | 1.249 | 1.273 |
| Gross Profit/Loss - EUR | -12.381 | 27.360 | 6.648 | 7.189 | 6.708 | -1.046 | -3.722 | 145 | 580 | 325 |
| Net Profit/Loss - EUR | -13.839 | 26.161 | 5.772 | 5.933 | 5.824 | -1.310 | -3.796 | 133 | 489 | 274 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Neo Sanguis Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 16.150 | 17.040 | 22.594 | 28.081 | 32.414 | 33.118 | 31.727 | 30.475 | 30.938 | 30.980 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 11.610 | 13.119 | 18.780 | 27.086 | 31.573 | 31.419 | 30.853 | 29.956 | 30.403 | 30.264 |
| Cash | 4.539 | 3.921 | 3.814 | 995 | 841 | 1.699 | 873 | 519 | 535 | 716 |
| Shareholders Funds | -10.461 | 15.806 | 9.059 | 9.159 | 14.806 | 13.215 | 9.127 | 9.288 | 9.749 | 9.968 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 26.611 | 1.234 | 13.535 | 18.922 | 17.608 | 19.902 | 22.600 | 21.187 | 21.190 | 21.012 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8690 - 8690" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Neo Sanguis Srl